Allogene Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $4,640 | $0 | $0 | $0 |
Gross Profit | 4,640 | -2,869 | -3,057 | -31,164 |
EBITDA | -39,689 | -39,438 | -35,440 | -37,959 |
EBIT | -42,334 | -42,307 | -38,497 | -41,056 |
Net Income | -42,677 | -42,607 | -38,810 | -41,400 |
Net Change In Cash | 4,640 | 0 | 0 | 0 |
Free Cash Flow | -32,146 | -12,922 | -27,599 | -29,931 |
Cash | 38,626 | 30,309 | 51,688 | 37,815 |
Basic Shares | 328,930 | 240,290 | 220,622 | 222,038 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $22 | $95 | $243 |
Gross Profit | -12,359 | 22 | 95 | 243 |
EBITDA | -177,452 | -243,327 | -313,066 | -321,154 |
EBIT | -189,811 | -256,966 | -327,265 | -335,449 |
Net Income | -190,886 | -257,590 | -327,265 | -329,815 |
Net Change In Cash | 0 | 22 | 95 | 243 |
Free Cash Flow | -149,632 | -200,994 | -239,249 | -225,710 |
Cash | 51,688 | 75,218 | 83,155 | 61,904 |
Basic Shares | 220,622 | 194,812 | 156,932 | 143,147 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.13 |
2026-03-31 | -$0.18 |
2025-12-31 | -$0.17 |
2025-09-30 | -$0.19 |